Stockscreener 앱 받기
13.13
3.17%
-0.43
시간 외 거래:
13.13
전일 마감가:
$13.56
열려 있는:
$13.44
하루 거래량:
196.89K
Relative Volume:
0.92
시가총액:
$442.05M
수익:
$99.99M
순이익/손실:
$-21.47M
주가수익비율:
-19.90
EPS:
-0.6597
순현금흐름:
$-11.34M
1주 성능:
-7.01%
1개월 성능:
-9.39%
6개월 성능:
+32.09%
1년 성능:
+11.74%
1일 변동 폭
$13.01
$13.74
1주일 범위
$13.01
$14.72
52주 변동 폭
$7.5625
$18.98
뉴로페이스 Stock (NPCE) Company Profile
명칭
Neuropace Inc
전화
(650) 237-2700
주소
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
13.13 | 456.52M | 99.99M | -21.47M | -11.34M | -0.6597 |
|
ABT
Abbott Laboratories
|
107.19 | 188.52B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
339.76 | 132.34B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.87 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.89 | 105.77B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
82.46 | 47.98B | 6.07B | 1.06B | 1.34B | 1.8063 |
뉴로페이스 Stock (NPCE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-01-21 | 개시 | UBS | Buy |
| 2024-03-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 개시 | Leerink Partners | Outperform |
| 2023-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-24 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 개시 | Lake Street | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-01-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 개시 | Robert W. Baird | Outperform |
| 2021-05-17 | 개시 | JP Morgan | Overweight |
| 2021-05-17 | 개시 | Morgan Stanley | Overweight |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 개시 | Wells Fargo | Overweight |
모두보기
뉴로페이스 주식(NPCE)의 최신 뉴스
NeuroPace (NASDAQ:NPCE) Upgraded at Wells Fargo & Company - MarketBeat
How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions - Yahoo Finance
NeuroPace, Inc. (NPCE) may report negative earnings: Know the trend ahead of next week's release - MSN
NeuroPace (NASDAQ:NPCE) Stock Rating Lowered by Wall Street Zen - MarketBeat
NeuroPace falls after setback in trial for neuromodulation system - MSN
Published on: 2026-03-12 04:41:05 - baoquankhu1.vn
NeuroPace at Leerink Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Key Factors Expected to Influence NPCE Stock Performance in 2026 - Bitget
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026 - TradingView
NPCE RNS System Explained: Growth Drivers and Setup for 2026 - TradingView
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand - Yahoo Finance
Neuropace (NPCE) chief medical officer sells $399k in stock - Investing.com Nigeria
Published on: 2026-03-09 06:34:24 - baoquankhu1.vn
NeuroPace appoints Patrick Williams as CFO - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Outlook: Will NeuroPace Inc stock benefit from M AJuly 2025 Technicals & Technical Buy Zone Confirmation - baoquankhu1.vn
NeuroPace (NASDAQ:NPCE) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Rate Cut: Will NeuroPace Inc stock benefit from M AEarnings Recap Summary & Long Hold Capital Preservation Plans - baoquankhu1.vn
Gains Recap: Is NeuroPace Inc a stock for growth or value investorsJuly 2025 WrapUp & Community Trade Idea Sharing - baoquankhu1.vn
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access - The Globe and Mail
NeuroPace to Present at the Leerink Global Healthcare Conference - Investing News Network
NeuroPace revenue up 24% to USD 26.6M in Q4 2025 - Medical Buyer
Boston Scientific to buy Penumbra in $14.5 billion deal - AOL.com
NeuroPace (NASDAQ:NPCE) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat
NeuroPace (NPCE) Loss Narrowing In Q4 Tests Bullish Profitability Narrative - simplywall.st
NeuroPace (NPCE) CMO sells shares under Rule 10b5-1 trading plan - Stock Titan
NeuroPace (NPCE) CEO reports 5,023-share tax-withholding disposition on RSU vesting - Stock Titan
Why NeuroPace Stock Was Inching Higher on Wednesday - AOL.com
Why NeuroPace Stock Was Inching Higher on Wednesday - The Motley Fool
Earnings call transcript: Neuropace beats Q4 2025 EPS forecast, stock dips - Investing.com Australia
NeuroPace (NPCE) Q4 2025 Earnings Call Transcript - The Globe and Mail
NeuroPace beats estimates as Q4 revenue surges 24%, sending shares up 15% By Investing.com - Investing.com South Africa
NeuroPace Q4 Earnings Call Highlights - MarketBeat
NeuroPace Beats Q1 Earnings Estimates - National Today
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
Neuropace earnings beat by $0.10, revenue topped estimates - Investing.com Canada
NeuroPace : Investor Presentation - marketscreener.com
NeuroPace reports $99.99M revenue, $(0.66) EPS in 10-K - TradingView
NeuroPace Q4 Loss Narrows, Revenue Rises; Shares Gain After Hours - marketscreener.com
NeuroPace (NASDAQ:NPCE) Posts Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
NeuroPace (NPCE) outlines RNS growth, trials and capital moves in 10-K - Stock Titan
NeuroPace Inc.: Fourth Quarter Earnings Overview - Bitget
Neuropace Inc. (NPCE) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
Press Release: NeuroPace Reports First Quarter 2025 Financial Results - 富途牛牛
NeuroPace beats estimates as Q4 revenue surges 24%, sending shares up 15% - Investing.com Nigeria
NeuroPace Inc.: Q4 Earnings Snapshot - marketscreener.com
NeuroPace (NASDAQ: NPCE) posts 25% 2025 growth and sets 2026 revenue, margin guidance - Stock Titan
Earnings Summary: NeuroPace Q4 - Benzinga
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook - Business Wire
뉴로페이스 (NPCE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.85%
1.86%
자본화:
|
볼륨(24시간):